Search our Database of Scientific Publications and Authors

I’m looking for a

    10988 results match your criteria Bone Marrow Transplantation[Journal]

    1 OF 220

    Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT.
    Bone Marrow Transplant 2018 Jan 17. Epub 2018 Jan 17.
    CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
    Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and non-malignant diseases. Despite increasing survival rates, long-term morbidity following HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction following HCT. Read More

    BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant 2018 Jan 17. Epub 2018 Jan 17.
    Department of Medicine, Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY, USA.

    Haploidentical hematopoietic stem cell transplant for patients with sickle cell disease using thiotepa, fludarabine, thymoglobulin, low dose cyclophosphamide, 200 cGy tbi and post transplant cyclophosphamide.
    Bone Marrow Transplant 2018 Jan 16. Epub 2018 Jan 16.
    Pediatric Stem Cell Transplant Program Children's Hospital at TriStar Centennial and Sarah Cannon Research Institute, Nashville, TN, 37203, USA.

    Complementary therapies for fatigue after hematopoietic stem cell transplantation: an integrative review.
    Bone Marrow Transplant 2018 Jan 16. Epub 2018 Jan 16.
    School of Nursing, University of Michigan, Ann Arbor, MI, USA.
    Fatigue after hematopoietic stem cell transplantation (HSCT) is a persistent problem that limits activities and causes distress. Complementary therapies have shown promising results in improving fatigue in several patient populations. However, it is unknown whether they have the same effect on fatigue in the HSCT population. Read More

    Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.
    Bone Marrow Transplant 2018 Jan 15. Epub 2018 Jan 15.
    Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA.
    Allogeneic hematopoietic cell transplantation (HCT) is associated with significant morbidity and mortality especially in the first year after HCT. In this study, we examine the long-term outcomes of patients who survived at least one year post HCT without evidence of relapse. We analyzed the records for 389 consecutive patients receiving an allogeneic transplant from 2005 to 2016 from a MRD, MUD, or haploidentical donor, who were alive and disease free at one year post-transplant. Read More

    Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.
    Bone Marrow Transplant 2018 Jan 15. Epub 2018 Jan 15.
    University of Heidelberg, Heidelberg, Germany.
    Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with mantle cell lymphoma who relapse after an autoSCT. However, the long-term efficacy of RIST and its curative potential have not been clearly demonstrated. We studied the long-term outcome of patients receiving a RIST for MCL as reported to the EBMT. Read More

    Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation.
    Bone Marrow Transplant 2018 Jan 15. Epub 2018 Jan 15.
    Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
    The impact of human leukocyte antigen (HLA) allele mismatch on transplant outcomes in haploidentical stem cell transplantation (haplo-SCT) has not been established. We retrospectively studied 595 patients with hematologic malignancy who received haplo-SCT. The impact of multiple HLA allele mismatches (HLA-A, -B, -C, -DRB1, and -DQB1) and each HLA allele mismatch on transplant outcomes was analyzed. Read More

    Haploidentical stem cell transplantation cures autoimmune hepatitis and cerebrovascular disease in a patient with sickle cell disease.
    Bone Marrow Transplant 2018 Jan 15. Epub 2018 Jan 15.
    Pediatric Hematology-Oncology Unit, Department of Women's and Children's Health, Azienda Ospedaliera-University of Padova, Padova, Italy.

    A prospective, randomized evaluation of the feasibility of exergaming on patients undergoing hematopoietic stem cell transplantation.
    Bone Marrow Transplant 2018 Jan 15. Epub 2018 Jan 15.
    Medizinische Klinik III, Klinik für Hämatologie, Onkologie und Palliativmedizin, Universitätsmedizin Rostock, Rostock, Germany.
    The positive effects of physical and sports therapy for strain dependent physical practice and improved quality of life (QoL) are well known. Nevertheless, the available capacities and problem-oriented therapies in the setting of hematopoietic stem cell transplantation (HSCT) are limited. We conducted a prospective, randomized study among 42 HSCT recipients in order to investigate the influence of exergaming on Nintendo Wii® or classical physiotherapy (PT) on physical fitness and psychological well-being. Read More

    Using liver elastography to diagnose sinusoidal obstruction syndrome in pediatric patients undergoing hematopoetic stem cell transplant.
    Bone Marrow Transplant 2018 Jan 15. Epub 2018 Jan 15.
    Children's Mercy Hospital, Kansas City, MO, USA.
    Sinusoidal obstruction syndrome (SOS) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT). Traditional ultrasound (US) has poor sensitivity and specificity. US shear wave elastography (SWE) is a newer technology that measures liver stiffness. Read More

    The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation.
    Bone Marrow Transplant 2018 Jan 15. Epub 2018 Jan 15.
    Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
    Haploidentical donors are now increasingly considered for transplantation in the absence of HLA-matched donors or when an urgent transplant is needed. Donor-specific anti-HLA antibodies (DSA) have been recently recognized as an important barrier against successful engraftment of donor cells, which can affect transplant survival. DSA appear more prevalent in this type of transplant due to higher likelihood of alloimmunization of multiparous females against offspring's HLA antigens, and the degree of mismatch. Read More


    Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
    Bone Marrow Transplant 2018 Jan 15. Epub 2018 Jan 15.
    Unit of Internal Medicine, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
    This mono-institutional observational study was conducted to determine incidence, severity, risk factors, and outcome of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in high-risk Ewing sarcoma (ES) patients treated with intravenous busulfan and melphalan (BU-MEL) followed by autologous stem cell transplantation (ASCT). During the past 10 years, 75 consecutive ES patients resulted evaluable for the analysis. After diagnosis of SOS/VOD, defibrotide therapy was started as soon as the medication was available. Read More


    Unmanipulated haploidentical transplantation conditioning with busulfan, cyclophosphamide and anti-thymoglobulin for adult severe aplastic anaemia.
    Bone Marrow Transplant 2018 Jan 15. Epub 2018 Jan 15.
    Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
    We conducted a retrospective analysis to evaluate outcomes of haploidentical transplantation in adult severe aplastic anaemia (SAA) patients. Fifty-one adults received haploidentical transplantation between May 2011 and December 2016. Patients were administered busulfan (Bu), cyclophosphamide (Cy) and anti-thymoglobulin (ATG) as conditioning regimens, followed by bone marrow and peripheral blood transplantation. Read More

    Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Hematology and BMT Unit, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132, Milano, Italy.
    Febrile neutropenia and sepsis are common and life-threatening complications in hematological diseases. This study was performed retrospectively in 514 patients treated for febrile neutropenia at our institute, to investigate the clinical usefulness of a molecular tool, LightCycler® SeptiFast test (SF), to promptly recognize pathogens causing sepsis in hematological patients. We collected 1837 blood samples of 514 consecutive hematological patients. Read More

    Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    CHRU Lille, Pôle Spécialités Médicales et Gérontologie (Medical Specialities and Gerontology), Service des Maladies du Sang (Department of Haematology), Secteur Allogreffe de Cellules Souches Hématopoïétiques (Allogeneic Stem Cell Transplantation Department), F59037, Lille, France.
    The question of the best donor type between haploidentical (HAPLO) and matched-related donors (MRD) for patients with advanced HL receiving an allogeneic hematopoietic cell transplantation (allo-HCT) is still debated. Given the lack of data comparing these two types of donor in the setting of non-myeloablative (NMA) or reduced-intensity (RIC) allo-HCT, we performed a multicentre retrospective study using graft-vs.-host disease-free relapse-free survival (GRFS) as our primary endpoint. Read More

    Association analysis between SUFU polymorphism rs17114808 and acute graft versus host disease after hematopoietic stem cell transplantation.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Department of General Paediatrics, Haematology/Oncology, University Children's Hospital, 72076, Tübingen, Germany.



    Successful management of concurrent acquired hemophilia A and a lupus anticoagulant in a pediatric hematopoietic stem cell transplant patient.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, MLC 11027, Cincinnati, OH, 45229, USA.

    Acute kidney injury following haplo stem cell transplantation: incidence, risk factors and outcome.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

    Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
    Allogeneic hematopoietic cell transplantation (alloHCT) in older patients requires the weighing of risks and benefits for this potentially curative treatment while facing age-related limitations. Comprehensive geriatric and quality of life (EORTC QLQ C-30) assessements (CGA/QOL) in addition to disease-specific data were obtained in 108 consecutive patients (≥60 years) pre-HCT, at day +30, +100, and +180. Median follow-up of 106 patients alive at alloHCT was 43. Read More

    Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    University Hospital Collegium Medicum UMK, Bydgoszcz, Poland.
    The role of donor CMV serostatus in the setting of non T-cell depleted haplo-HSCT with post-transplant cyclophosphamide (PT-Cy) has not been specifically addressed so far. Here we analyzed the impact of the donor CMV serological status on the outcome of 983 CMV seropositive (CMV+), acute leukemia patients receiving a first, non T-cell depleted haplo-HSCT registered in the EBMT database. The 1-year NRM was 21. Read More

    Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Clinica di Ematologia, Università Politecnica delle Marche, Ancona, Italy.
    Predicting mobilization failure before it starts may enable patient-tailored strategies. Although consensus criteria for predicted PM (pPM) are available, their predictive performance has never been measured on real data. We retrospectively collected and analyzed 1318 mobilization procedures performed for MM and lymphoma patients in the plerixafor era. Read More


    Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Hematology and Bone Marrow Transplantation Program, Hospital Israelita Albert Einstein, São Paulo, Brazil.
    Allogeneic hematopoietic stem cell transplantation (HSCT) is the only treatment that enhances survival and stabilizes neurologic symptoms in X-linked adrenoleukodystrophy (X-ALD) with cerebral involvement, a severe demyelinating disease of childhood. Patients with X-ALD who lack a well-matched HLA donor need a rapid alternative. Haploidentical HSCT using post transplant cyclophosphamide (PT/Cy) has been performed in patients with malignant and nonmalignant diseases showing similar outcomes compared to other alternative sources. Read More

    Haploidentical hematopoietic SCT using helical tomotherapy for total-body irradiation and targeted dose boost in patients with high-risk/refractory acute lymphoblastic leukemia.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Department of Hematology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong province, P.R. China.
    A novel conditioning regimen using helical tomotherapy (HT) was developed to deliver 10 Gy for total body irradiation (TBI) and simultaneously augment dose to 12 Gy for targeted dose boost to total marrow, central nervous system leukemia, and extramedullary disease sites in patients with high-risk or relapsed/refractory acute lymphoblastic leukemia (ALL) receiving haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT). Fourteen patients were included, eight of these patients were in first complete remission (CR1), one was in CR2, one had a partial response and four patients had refractory disease at transplantation. The median delivered average dose was 11. Read More

    Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Department of Hematology, University Hospital Saint Antoine, APHP, Paris, France.
    Antithymocyte globulin (ATG) is commonly used for graft-vs.-host disease (GVHD) prophylaxis in unrelated donor allogeneic transplantation (Allo-HSCT). However, its use is still controversial in matched sibling donor (MSD) Allo-HSCT, notably after reduced intensity conditioning (RIC). Read More

    Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Centro de Hematología y Medicina Interna de Puebla, Puebla, Puebla, Mexico.
    We studied rates of granulocyte and platelets recovery in 359 consecutive subjects receiving blood cell infusions in the context of autotransplants for plasma cell myeloma (N = 216) and lymphomas (N = 143). Blood cells were mobilised with filgrastim given for 4-5 days and collected after a median of 2 (range, 1-2) apheresis. Apheresis products were stored at 4° C for a median of 3 days (range, 2-6 days). Read More


    Donor HSCs with a preexisting ASXL1-mutation led to the development of FLT3-ITD positive AML in the donor and FLT3-ITD negative AML in the recipient after unrelated transplant.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Department of Hematology, Henan Provincial People's Hospital and Zhengzhou University People's Hospital, #7 Weiwu Road, Zhengzhou, Henan, 450003, China.

    Intravesical cidofovir application in BK virus cystitis after allogeneic hematopoetic stem cell transplantation (HSCT) is safe and highly effective.
    Bone Marrow Transplant 2018 Jan 12. Epub 2018 Jan 12.
    Medical Clinic III for Oncology, Hematology, Immunoncology and Rheumatology, University Hospital Bonn (UKB), Bonn, Germany.

    Sleep disruption among cancer patients following autologous hematopoietic cell transplantation.
    Bone Marrow Transplant 2017 Dec 21. Epub 2017 Dec 21.
    Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
    Despite a high prevalence of sleep disruption among hematopoietic cell transplant (HCT) recipients, relatively little research has investigated its relationships with modifiable cognitive or behavioral factors or used actigraphy to characterize sleep disruption in this population. Autologous HCT recipients who were 6-18 months post transplant completed self-report measures of cancer-related distress, fear of cancer recurrence, dysfunctional sleep cognitions, and inhibitory sleep behaviors upon enrollment. Patients then wore an actigraph for 7 days and completed a self-report measure of sleep disruption on day 7 of the study. Read More

    Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of Italy. A GITMO/IBMDR study.
    Bone Marrow Transplant 2017 Dec 21. Epub 2017 Dec 21.
    Hematology, University Hospital Sant'Orsola-, Malpighi, Bologna, Italy.
    Hematopoietic Stem Cell Transplantation activity levels vary across European countries. No data are available on the homogeneity of access to the transplant procedure for patient with leukaemia, within any European country. We measured homogeneity of the rate of alternative donor search in patients affected by acute leukaemia resident in each Italian region and macro-region during years 2010-2013. Read More

    Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma.
    Bone Marrow Transplant 2017 Dec 21. Epub 2017 Dec 21.
    Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, and Department of Medicine, University of Toronto, Toronto, ON, Canada.

    No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia.
    Bone Marrow Transplant 2017 Dec 21. Epub 2017 Dec 21.
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
    Recent studies suggest improved survival in patients with severe aplastic anemia receiving hematopoietic cell transplant (HCT) from unrelated donors with longer telomeres. Here, we tested whether this effect is generalizable to patients with acute leukemia. From the Center for International Blood and Marrow Transplant Research (CIBMTR®) database, we identified 1097 patients who received 8/8 HLA-matched unrelated HCT for acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL) between 2004 and 2012 with myeloablative conditioning, and had pre-HCT blood sample from the donor in CIBMTR repository. Read More

    Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation.
    Bone Marrow Transplant 2017 Dec 21. Epub 2017 Dec 21.
    Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

    Reduction of DMSO concentration in cryopreservation mixture from 10% to 7.5% and 5% has no impact on engraftment after autologous peripheral blood stem cell transplantation: results of a prospective, randomized study.
    Bone Marrow Transplant 2017 Dec 21. Epub 2017 Dec 21.
    Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Institute - Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15 Street, 44-101, Gliwice, Poland.
    The procedure of autologous peripheral blood stem cell transplantation (autoPBSCT) requires cryopreservation of cells in a mixture containing dimethyl sulfoxide (DMSO). DMSO is necessary to secure cell viability, however, its infusion may be toxic to stem cell recipient. The aim of this study was to prospectively evaluate the impact of DMSO concentration on engraftment after autoPBSCT. Read More

    Endocrine complications in patients with transfusion-dependent thalassaemia after haemopoietic stem cell transplantation.
    Bone Marrow Transplant 2017 Dec 21. Epub 2017 Dec 21.
    Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, Hong Kong, China.

    Successful hematopoietic stem cell transplantation after myeloablative conditioning in three patients with dedicator of cytokinesis 8 deficiency (DOCK8) related Hyper IgE syndrome.
    Bone Marrow Transplant 2017 Dec 21. Epub 2017 Dec 21.
    Faculty of Medicine, Department of Pediatrics, Division of Bone Marrow Transplantation Unit, Hacettepe University, Sıhhiye, 06100, Ankara, Turkey.

    Deconditioning, fatigue and impaired quality of life in long-term survivors after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant 2017 Dec 21. Epub 2017 Dec 21.
    l'institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, 44000, France.
    Long-term survivors after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at high risk for treatment-related adverse events, that may worsen physical capacity and may induce fatigue and disability. The aims of this prospective study were to evaluate exercise capacity in allotransplant survivors and its relationship with fatigue and disability. Patient-reported outcomes and exercise capacity were evaluated in 71 non-relapse patients 1 year after allo-HSCT, using validated questionnaires, cardiopulmonary exercise testing (CPET) with measure of peak oxygen uptake (peakVO2) and deconditioning, pulmonary function testing, echocardiography and 6-min walk test. Read More

    1 OF 220